That's the reason those types of trials require so many patients and have to be run multiple times. It's crazy hard to get approval obviously but if you understand the science of alzheimer's its easy to see why they fail. Best decision this company made was to target late stage.
I thought the part of the audio where Alkon was essentially saying they interviewer was comparing apples to oranges with the different drug scores was amusing as obviously the interviewer with a science background couldn't understand the different of Aricept or Namenda beating a true placebo baseline by a couple points AND in early stages vs NTRP having to beat a current SOC placebo stabilized as much as they can be on those type of drugs and in LATE stage...but we still even beat that.
When Alkon was asked about stat significance and he said yeah at the .0001 level, I would have loved to see the look on the interviewers face.
News 
Market Data 
Discover 
